Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hong Kong
Biotech
HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial
HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug.
James Waldron
Nov 25, 2024 9:20am
Zephyrm seeks Hong Kong IPO to fund phase 3 cell therapy trials
Oct 2, 2024 8:19am
Duality seeks cash for ADC trials as IPO wave spreads to Asia
Aug 27, 2024 9:20am
Chinese CRO Tigermed debuts new HQ den in Hong Kong
Aug 23, 2023 9:20am
BeiGene taps rising Hong Kong star to create targeted mRNA drugs
Jul 6, 2022 9:10am
Oculis improves its vision with CMO Chang from Novartis
Oct 7, 2021 10:59am
